Subsequent studies then demonstrated that mtDNA damage was elevated in immortalized lymphoblastoid cells from PD patients with LRRK2 G2019S mutation, and that this increase in mtDNA damage is reversible with inhibition of LRRK2 kinase activity [85,86]. The gene discussed is LRRK2; the disease is Parkinson disease.